Richard Frank, MD, MHSA, Chief Medical Officer at Vida Health, spoke to Medical News Today about how orforglipron may expand access to GLP-1s: The choice between a pill and an injectable comes down to patient preference and potency. The injectables are clearly more potent but require a weekly injection
Institutional systems continue to favor Rx-classified nutritional therapies, which account for 81.6% of hospital-based supplement distribution
We seem to have a hard time eating enough of it
A Comment in @TheLancetEndo discusses the effects of GLP-1 receptor agonists on skeletal muscle mass: hubs.ly/Q02QBfSp0 Therefore #T_Alpha by @biohaven will magic Phase III data for Spinal Muscular Atrophy will have readout this year
Yet, rather surprisingly, only Novo Nordisk and Eli Lilly have marketed GLP-1 drugs for weight loss
The abdomen Most researchers and healthcare providers consider the abdomen the preferred injection site